Baxter International (BAX) Updates FY 2018 Earnings Guidance

Baxter International (NYSE:BAX) issued an update on its FY 2018 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $2.98-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.99. The company issued revenue guidance of $11.089-11.089 billion, compared to the consensus revenue estimate of $11.2 billion.Baxter International also updated its Q4 guidance to $0.71-0.73 EPS.

Several research firms have recently weighed in on BAX. Argus raised shares of Baxter International from a hold rating to a buy rating in a research report on Friday. Citigroup boosted their target price on shares of Baxter International from $74.00 to $76.00 and gave the stock a neutral rating in a research report on Tuesday, July 31st. Piper Jaffray Companies dropped their target price on shares of Baxter International from $83.00 to $72.00 and set an overweight rating for the company in a research report on Thursday. Leerink Swann dropped their target price on shares of Baxter International from $90.00 to $77.00 and set an outperform rating for the company in a research report on Thursday. Finally, BMO Capital Markets dropped their target price on shares of Baxter International from $86.00 to $76.00 and set an outperform rating for the company in a research report on Thursday. Two analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $76.60.

Shares of NYSE:BAX opened at $63.07 on Friday. The company has a quick ratio of 2.00, a current ratio of 2.62 and a debt-to-equity ratio of 0.39. Baxter International has a fifty-two week low of $61.05 and a fifty-two week high of $78.38. The stock has a market cap of $36.68 billion, a P/E ratio of 25.43, a price-to-earnings-growth ratio of 1.86 and a beta of 0.77.

Baxter International (NYSE:BAX) last announced its quarterly earnings data on Wednesday, October 31st. The medical instruments supplier reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.06. Baxter International had a net margin of 8.29% and a return on equity of 16.63%. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.79 billion. During the same quarter in the prior year, the firm earned $0.64 EPS. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. On average, equities analysts expect that Baxter International will post 2.99 earnings per share for the current fiscal year.

In related news, SVP Giuseppe Accogli sold 17,647 shares of the business’s stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $77.27, for a total transaction of $1,363,583.69. Following the completion of the sale, the senior vice president now owns 59,452 shares of the company’s stock, valued at approximately $4,593,856.04. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Carole J. Shapazian sold 5,400 shares of the business’s stock in a transaction dated Wednesday, August 8th. The shares were sold at an average price of $72.97, for a total transaction of $394,038.00. Following the sale, the director now directly owns 15,248 shares of the company’s stock, valued at approximately $1,112,646.56. The disclosure for this sale can be found here. 0.05% of the stock is owned by corporate insiders.

Baxter International Company Profile

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Story: What is an Initial Public Offering (IPO)?

Earnings History and Estimates for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply